En español

Menu

Publications

Quick Links

Alabama Opioid Summary

Revised May 2019

Drug Overdose Deaths

In 2017, there were more than 70,200 drug overdose deaths in the U.S.–an age-adjusted rate of 21.7 per 100,000 persons. The sharpest increase occurred among deaths involving fentanyl and fentanyl analogs (other synthetic narcotics) with more than 28,400 overdose deaths in 2017.

The age-adjusted rate of drug overdose deaths increased significantly in Alabama by 11.1 percent from 2016 (16.2 per 100,000) to 2017 (18.0 per 100,000). While the majority of drug overdose deaths in 2017 involved an opioid, overdose deaths involving opioids are not included for the state because the data reported did not meet inclusion criteria (see Scholl L, et al. MMWR Morbidity and Mortality Weekly Report 2019;67:1419–1427).

See textFigure 1. Drug overdose deaths, rate per 100,000 persons, in the U.S. and Alabama. Source: CDC WONDER.

Opioid Pain Reliever Prescriptions

In 2017, Alabama providers wrote 107.2 opioid prescriptions for every 100 persons (Figure 2). This was the highest prescribing rate in the country and was almost twofold greater than the average U.S. rate of 58.7 prescriptions. Still, this represents a 25 percent decline in Alabama opioid prescriptions, since 2013 (CDC).

See text Figure 2. The U.S. and Alabama opioid prescribing rate per 100 persons. Source: CDC and IQVIA Xponent 2006–2017.

Neonatal Abstinence Syndrome (NAS)

NAS or neonatal opioid withdrawal syndrome (NOWS) may occur when a pregnant woman uses drugs such as opioids during pregnancy. A recent national study showed a fivefold increase in the incidence of NAS/NOWS between 2004 and 2014, from 1.5 cases per 1,000 hospital births to 8.0 cases per 1,000 hospital births―that is one baby born with NAS/NOWS every 15 minutes in the United States. During the same period, hospital costs for NAS/NOWS births increased from $91 million to $563 million, after adjusting for inflation (Figure 3). State specific data on the rate of babies born with NAS/NOWS in Alabama is unavailable.

See textFigure 3. NAS/NOWS Incidence Rate and Hospital Costs for Treatment in the United States. Source: T N.A.Winkelman, et al., 2018.

HIV Prevalence and HIV Diagnoses Attributed to Injection Drug Use (IDU)

See textFigure 4. Alabama: Estimated percent of male vs. female with new HIV diagnoses, by transmission category, 2016. Source: CDC and www.AIDSVU.org.
  • U.S. Incidence: In 2016, 9 percent (3,480) of the 39,589 new diagnoses of HIV in the United States were attributed to IDU. Among males, 6.3 percent (2,530) of new cases were transmitted via IDU or male-to-male contact and IDU. Among females, 2.3 percent (950) were transmitted via IDU (CDC).
  • U.S. Prevalence: In 2016, 991,447 Americans were living with a diagnosed HIV infection—a rate of 306.6 cases per 100,000 persons. Among males, 19.9 percent (150,466) contracted HIV from IDU or male-to-male contact and IDU while 21 percent (50,154) of females were living with HIV attributed to IDU (CDC).
  • State Incidence: Of the new HIV cases in 2016, 533 occurred in Alabama. Of those, 5.6 percent occurred in males and were attributed to IDU or male-to-male contact and IDU. Among females, 7.9 percent of new HIV cases were attributed to IDU (Figure 4) (AIDSVu).
  • State Prevalence: In 2015, an estimated 12,316 persons were living with a diagnosed HIV infection in Alabama—a rate of 302 cases per 100,000 persons. Of those, 12.6 percent occurred in males and were attributed to IDU or male-to-male contact and IDU. Among females, 15 percent were living with HIV attributed to IDU (AIDSVu).

Hepatitis C (HCV) Prevalence and HCV Diagnoses Attributed to Injection Drug Use1

  • U.S. Incidence: In 2016, there were an estimated 41,200 new cases of acute HCV(CDC). Among case reports that contain information about IDU, 68.6 percent indicated use of injection drugs (CDC).
  • U.S. Prevalence: An estimated 2.4 million Americans are living with HCV based on 2013-2016 annual averages (CDC).
  • State Incidence: There were approximately 32 new cases of acute HCV (0.7 per 100,000 persons) reported in Alabama in 2016 (CDC).
  • State Prevalence: In Alabama, there are an estimated 31,300 persons living with Hepatitis C (2013-2016 annual average), a rate of 840 cases per 100,000 persons (HepVu).

The National Institute of Health Funds Center of Excellence in Pain Education

This is the logo for the NIH Pain Consortium: Centers of Excellence in Pain Education.

Alabama is home to one of the eleven Centers of Excellence in Pain Education (CoEPEs): The University of Alabama at Birmingham. The CoEPEs act as hubs for the development, evaluation, and distribution of pain management curriculum resources for medical, dental, nursing, pharmacy and other schools to improve how health care professionals are taught about pain and its treatment.

Additional Resources

NIH RePORTER FY2018 NIH-funded projects related to opioid use and use disorder in Alabama: 1

Notes

  1. Not all states collect or report data on the incidence or prevalence of Hepatitis C or on how Hepatitis C is transmitted. When available, the data will be included.
  2. Actual acute cases estimated to be 13.9 times the number of reported cases in any year.

This page was last updated May 2019

Get this Publication

Opioid Summaries by State

Cite this article

NIDA. (2019, May 22). Alabama Opioid Summary. Retrieved from https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state/alabama-opioid-summary

press ctrl+c to copy

NIH HEAL (Helping to End Addiction Long-term) Initiative

New Opioid Overdose Materials for Patients

Easy-to-read Drug Facts

This Is NIDA: Opioids

This Is NIDA: Opioids

The National Institute on Drug Abuse's research-based, informative video series "This Is NIDA," addresses the topic of OPIOIDS.